Table 1.
Patients’ characteristics. N: number of cases; ADT: androgen deprivation therapy; ECOG: Eastern Cooperative Oncology Group; PSA: prostate-specific antigen; CRPC: castration-resistant prostate cancer; NA: not available.
| Patients Eligible (Enrolled), N | 125 (133) |
|---|---|
| Age (years) | |
| Median (range) | 66.6 (46.3–83.4) |
| Tumor origin, N (%) | |
| Primary | 117 (93.6) |
| Metastatic | 8 (6.4) |
| Stage at diagnosis, N (%) | |
| <IV | 9 (7.2) |
| IV | 116 (92.8) |
| Gleason sum at diagnosis, N (%) | |
| ≤7 | 22 (17.6) |
| ≥8 | 102 (81.6) |
| NA | 1 (0.8) |
| Presence of bone metastases, N (%) | |
| Yes | 112 (89.6) |
| No | 13 (10.4) |
| Presence of visceral metastases, N (%) | |
| Yes | 25 (20) |
| No | 100 (80) |
| Location of visceral metastases, N (%) | |
| Lung | 20 (80) |
| Liver | 7 (28) |
| Pleural | 1 (4) |
| NA | 1 (4) |
| Disease volume, N (%) | |
| High | 98 (78.4) |
| Low | 26 (20.8) |
| NA | 1 (0.8) |
| ECOG performance status score, N (%) | |
| 0 | 54 (43.2) |
| 1 or 2 | 69 (55.2) |
| NA | 2 (1.6) |
| Baseline PSA (ng/mL) at diagnosis | |
| Median (range) | 83.2 (1.8–7448) |
| Baseline lactate dehydrogenase (U/L) | |
| Median (range) | 316 (116–1023) |
| Time from ADT to docetaxel treatment, N (%) | |
| <3 months | 106 (84.8) |
| ≥3 months | 19 (15.2) |
| First line treatment in CRPC, N (%) | |
| Abiraterone or enzalutamide | 77 (80.2) |
| Taxanes | 5 (5.2) |
| Other treatments | 5 (5.2) |
| No treatment | 4 (4.2) |
| NA | 5 (5.2) |